Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment

Background:. Chronic wounds represent a significant financial burden to the healthcare system and a quality-of-life burden to patients. Many chronic wounds have elevated bioburden in the form of biofilm, which has been associated with delayed wound healing. This study examined the use of a native ty...

Full description

Bibliographic Details
Main Author: Alisha R. Oropallo, MD, FACS
Format: Article
Language:English
Published: Wolters Kluwer 2019-01-01
Series:Plastic and Reconstructive Surgery, Global Open
Online Access:http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000002047
_version_ 1818162064867196928
author Alisha R. Oropallo, MD, FACS
author_facet Alisha R. Oropallo, MD, FACS
author_sort Alisha R. Oropallo, MD, FACS
collection DOAJ
description Background:. Chronic wounds represent a significant financial burden to the healthcare system and a quality-of-life burden to patients. Many chronic wounds have elevated bioburden in the form of biofilm, which has been associated with delayed wound healing. This study examined the use of a native type I collagen matrix with the antimicrobial polyhexamethylene biguanide (PCMP) in the management of bioburden and treatment of chronic, nonhealing wounds over 12 weeks. Methods:. A prospective case series of PCMP enrolled adults ≥18 years old with a nonhealing wound. At week 0, the wound was prepared by sharp or mechanical debridement. Patients received standard wound care plus PCMP applications at week 0 and then weekly up to week 12 at the investigator’s discretion. Dressings were applied over PCMP to fix it in place. At each visit, wounds were assessed for the extent of healing and signs of wound infection. Results:. Of the 41 wounds studied, 44% were pressure ulcers, 22% were surgical wounds, 12% were venous ulcers, 10% were diabetic ulcers, and 12% were another type. The median (interquartile range) baseline wound area was 7.2 (14.9) cm2, and the mean wound duration was 103 weeks. Of the 41 wounds, 73% demonstrated a reduction in wound area at 12 weeks, and 37% achieved complete wound closure, with a mean time of 6.7 weeks to complete closure. Conclusion:. PCMP treatment appeared to positively impact the course of wound healing in a variety of complex, chronic wounds that were unresponsive to prior treatment.
first_indexed 2024-12-11T16:27:44Z
format Article
id doaj.art-324f44dabea6410fa665ec47d258454c
institution Directory Open Access Journal
issn 2169-7574
language English
last_indexed 2024-12-11T16:27:44Z
publishDate 2019-01-01
publisher Wolters Kluwer
record_format Article
series Plastic and Reconstructive Surgery, Global Open
spelling doaj.art-324f44dabea6410fa665ec47d258454c2022-12-22T00:58:41ZengWolters KluwerPlastic and Reconstructive Surgery, Global Open2169-75742019-01-0171e204710.1097/GOX.0000000000002047201901000-00019Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound TreatmentAlisha R. Oropallo, MD, FACS0From the *Department of Surgery, Northwell Health, Lake Success, N.Y.Background:. Chronic wounds represent a significant financial burden to the healthcare system and a quality-of-life burden to patients. Many chronic wounds have elevated bioburden in the form of biofilm, which has been associated with delayed wound healing. This study examined the use of a native type I collagen matrix with the antimicrobial polyhexamethylene biguanide (PCMP) in the management of bioburden and treatment of chronic, nonhealing wounds over 12 weeks. Methods:. A prospective case series of PCMP enrolled adults ≥18 years old with a nonhealing wound. At week 0, the wound was prepared by sharp or mechanical debridement. Patients received standard wound care plus PCMP applications at week 0 and then weekly up to week 12 at the investigator’s discretion. Dressings were applied over PCMP to fix it in place. At each visit, wounds were assessed for the extent of healing and signs of wound infection. Results:. Of the 41 wounds studied, 44% were pressure ulcers, 22% were surgical wounds, 12% were venous ulcers, 10% were diabetic ulcers, and 12% were another type. The median (interquartile range) baseline wound area was 7.2 (14.9) cm2, and the mean wound duration was 103 weeks. Of the 41 wounds, 73% demonstrated a reduction in wound area at 12 weeks, and 37% achieved complete wound closure, with a mean time of 6.7 weeks to complete closure. Conclusion:. PCMP treatment appeared to positively impact the course of wound healing in a variety of complex, chronic wounds that were unresponsive to prior treatment.http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000002047
spellingShingle Alisha R. Oropallo, MD, FACS
Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
Plastic and Reconstructive Surgery, Global Open
title Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
title_full Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
title_fullStr Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
title_full_unstemmed Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
title_short Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment
title_sort use of native type i collagen matrix plus polyhexamethylene biguanide for chronic wound treatment
url http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000002047
work_keys_str_mv AT alisharoropallomdfacs useofnativetypeicollagenmatrixpluspolyhexamethylenebiguanideforchronicwoundtreatment